Tonghua Dongbao Pharmaceutical(600867.SH): Liraglutide injection obtains overseas drug registration certificate.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that it has recently received the drug registration certificate for Liraglutide injection issued by the National Health Regulatory Authority of Nicaragua (ANRS) (registration number: 06000760426). Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that activates human GLP-1 receptors, promoting insulin secretion from the pancreas. It is used for controlling blood sugar in diabetes patients. The approval of the Liraglutide injection by the National Health Regulatory Authority of Nicaragua (ANRS) marks another important breakthrough for the company in the Central American market, following the approval of the recombinant human insulin injection in 2025. This achievement allows for a coordinated approach in the market for both insulin and GLP-1 products, providing a more comprehensive metabolic disease treatment option for local patients. It also enriches the company's international product line, enhances brand image, and expands international business.